Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol)

Drug Development and Industrial Pharmacy

Volumn 36, Issue 4, 2010, Pages 439-448

  Wu, Lifang ^a   Tang, Cui ^a   Yin, Chunhua ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Drug delivery system; Folate; Paclitaxel; Pharmacokinetics; Solid liquid lipid nanoparticles; Tumor inhibition rate

Indexed keywords

FOLATE POLYETHYLENE GLYCOL PHOSPHATIDYLETHANOLAMINE; FOLIC ACID; PACLITAXEL; PHOSPHATIDYLETHANOLAMINE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CREMOPHOR; GLYCEROL; MACROGOL DERIVATIVE; NANOPARTICLE; POLYMER; SERUM ALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DIALYSABILITY; DRUG EFFECT; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; RAT; SARCOMA 180; SPRAGUE DAWLEY RAT; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; SOLUBILITY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FOLIC ACID; GLYCEROL; MALE; MICE; NANOPARTICLES; PACLITAXEL; POLYETHYLENE GLYCOLS; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SARCOMA 180; SERUM ALBUMIN; SOLUBILITY;

EID: 77749295726     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903244472     Document Type: Article

References (38)

1. Horwitz SB. (1992). Mechanism of action of taxol. Trends Pharmacol Sci, 13:134-6.
2. Spencer CM, Faulds D. (1994). Paclitaxel. Drugs, 48:794-847.
3. Gregory RE, DeLisa AF. (1993). Paclitaxel: A new antineoplastic agent for refractory ovarian cancer. Clin Pharm, 12:401-15.
4. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. (2003). Paclitaxel resistance: Molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets, 3:1-19.
5. Lee J, Lee SC, Acharya G, Chang CJ, Park K. (2003). Hydrotropic solubilization of paclitaxel: Analysis of chemical structures for hydrotropic property. Pharm Res, 20:1022-30.
6. Henningsson A, Karlsson MO, Vigano L. (2001). Mechanism based pharmacokinetic model for paclitaxel. J Clin Oncol, 19:4065-73.
7. Szebeni J, Muggia FM, Alving CR. (1998). Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study. J Natl Cancer Inst, 90:300-6.
8. Song D, Hsu LF, Au JLS. (1996). Binding of paclitaxel to plastic glass container and protein under in vitro conditions. J Pharm Sci, 85:29-31.
9. Paradis R, Page M. (1998). New active paclitaxel amino acids derivatives with improved water solubility. Anticancer Res, 18:2711-6.
10. Constantinides PP, Tustian A, Kessler DR. (2004). Tocol emulsion for drug solubilization and parenteral delivery. Adv Drug Deliv Rev, 56:1243-55.
11. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 23:7794-803.
12. Gradishar WJ. (2006). Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother, 7(8):1041-53.
13. Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm, 50:161-77.
14. Chen DB, Yang TZ, Lu WL, Zhang Q. (2001). In vitro and in vivo study of two types of long-circulating solid lipid nanoparticless containing paclitaxel. Chem Pharm Bull, 49:1444-7.
15. Wissing SA, Kayser O, Müller RH. (2004). Solid lipid nanoparticless for parenteral drug delivery. Adv Drug Deliv Rev, 56:1257-72.
16. Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mäder K. (2004). Investigations on the structure of solid lipid nanoparticless (SLN) and oil-loaded solid lipid nanoparticless by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release, 95:217-27.
17. Torchilin VP, Trubetskoy VS. (1995). Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev, 16:141-55.
18. Laginha K, Mumbengegwi D, Allen T. (2005). Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotoxicity. Biochim Biophys Acta, 1711:25-32.
19. Campbell IG, Jones TA, Foulkes WD, Trowsdale J. (1991). Folate-binding protein is a marker for ovarian cancer. Cancer Res, 51:5329-38.
20. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL, Old LJ, Rettig WJ. (1993). Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol, 142:557-67.
21. Ross JF, Chaudhuri PK, Ratnam M. (1994). Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer, 73:2432-43.
22. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. (2005). Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem, 338:284-93.
23. Leamon CP, Low PS. (1994). Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Target, 2:101-12.
24. Lee RJ, Low PS. (1994). Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem, 269:3198-204.
25. Lee RJ, Low PS. (1995). Folate-mediated tumor cell targeting of liposome entrapped doxorubicin in vitro. Biochim Biophys Acta, 1233:134-44.
26. Wang S, Lee RJ, Mathias CJ, Green MA, Low PS. (1996). Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjug Chem, 7(1):56-62.
27. Li S, Deshmukh HM, Huang L. (1998). Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm Res, 15:1540-5.
28. Shinoda T, Takagi A, Maeda A, Kagatani S, Konno Y, Hashida M. (1998). In vivo fate of folate-BSA in non-tumor- and tumor-bearing mice. J Pharm Sci, 87:1521-6.
29. Zhou W, Yuan X, Wilson A, Yang L, Mokotoff M, Pitt B, et al. (2002). Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug Chem, 13:1220-5.
30. Ke CY, Mathias CJ, Green MA. (2003). The folate receptor as a molecular target for tumor-selective radionuclide delivery. Nucl Med Biol, 30:811-7.
31. Carlsson G, Gullberg B, Hafstrom L. (1983). Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol, 105:20-3.
32. Jung KO, Park SY, Park KY. (2006). Longer aging time increases the anticancer and antimetastatic properties of doenjang. Nutrition, 22:539-45.
33. Liu M, Xu W, Xu LJ, Zhong GR, Chen SL. (2005). Synthesis and biological evaluation of diethylenetriamine pentaacetic acid-polyethylene glycol-folate: A new folate-derived, 99mTc-based radiopharmaceutical. Bioconjug Chem, 16:1126-32.
34. Sahoo SK, Ma W, Labhasetwar V. (2004). Efficacy of transferrinconjugated paclitaxel-loaded nanoparticless in a murine model of prostate cancer. Int J Cancer, 112:335-40.
35. Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, et al. (2007). Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release, 120:169-77.
36. Lawrence JM, Petitti DB, Watkins M, Umekubo MA. (1999). Trends in serum folate after food fortification. Lancet, 354:915-6.
37. Yoo HS, Park TG. (2004). Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release, 96:273-83.
38. Zhang LK. (2005). Study on drug delivery system of folate-receptor- mediated mitoxantrone albumin nanoparticless targeting ovarian cancer cell. Doctoral dissertation. Sichuan University, China.